Want to see NDRA full AI Analyst Report?
Top Page
ENDRA Life Sciences
(NASDAQ:NDRA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▼(-7.41% Downside)
Action:Reiterated
Date:08/18/26
The score is held down primarily by very weak financial performance (no revenue, ongoing losses, and significant cash burn implying continued funding risk). Technicals add further pressure with the stock trading below major moving averages and a negative MACD. Corporate events provide some offset through regained Nasdaq compliance and a potentially transformative merger/financing plan, but these benefits are balanced by monitoring-period and execution/control risks; valuation is limited by negative earnings and no dividend data.
Positive Factors
Low Leverage
Minimal debt reduces interest and refinancing pressure, preserving flexibility while ENDRA develops its platform or pursues strategic alternatives. This is a meaningful balance-sheet advantage, although it does not offset the company’s reliance on external funding.
Negative Factors
No Commercial Revenue
Persistent zero revenue shows that ENDRA has not demonstrated commercial adoption of its imaging technology. Without customers or recurring sales, the business lacks an internally funded growth engine and remains dependent on financing, partnerships, or a successful strategic transaction.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt reduces interest and refinancing pressure, preserving flexibility while ENDRA develops its platform or pursues strategic alternatives. This is a meaningful balance-sheet advantage, although it does not offset the company’s reliance on external funding.
Read all positive factors
ENDRA Life Sciences (NDRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.73M
Dividend YieldN/A
Average Volume (3M)514.97K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue GrowthN/A
EPS Growth98.17%
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-6.33
Shares Outstanding1,499,838
10 Day Avg. Volume1,472,495
30 Day Avg. Volume514,968
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.58
Price to Sales (P/S)0.00
P/FCF Ratio-0.69
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$25.00Price Target Upside414.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.54
Revenue Forecast (FY)N/A
ENDRA Life Sciences Business Overview & Revenue Model
Company Description
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off interna...
How the Company Makes Money
null...
ENDRA Life Sciences Earnings Call Summary
Earnings Call Date:Aug 22, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Neutral
The earnings call presented several strategic initiatives aimed at improving ENDRA's focus and operational efficiency, alongside positive developments in management, regulatory strategy, and intellectual property. However, financial challenges and stock performance issues remain concerns.Positive Updates
Enhanced Management Team
ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.
Negative Updates
Reverse Stock Split Challenges
The reverse stock split intended to maintain NASDAQ listing was derailed by high volume of exercised warrants, resulting in trading below $1, creating uncertainty for the company's stock performance.
Read all updates
Q2-2024 Updates
Positive
Negative
Enhanced Management Team
ENDRA has strengthened its management team by adding two experienced operators: Richard Jacroux as CFO and Ziad Rouag as Head of Clinical and Regulatory Affairs, both bringing significant expertise in transforming technology companies and navigating regulatory processes.
Read all positive updates
Company Guidance
During the ENDRA Life Sciences Q2 2024 earnings call, significant guidance was provided by the management team, outlining various strategic initiatives. Notably, the company has completed a 1-for-50 reverse stock split aimed at maintaining its NASDAQ listing, though recent high warrant exercise volumes have impacted their stock price adversely. Six key operational changes were introduced, including the enhancement of the management team with the addition of a seasoned CFO and a new Head of Clinical and Regulatory Affairs. The company plans to conduct a statistically-powered multicenter prospective clinical trial, expanding the number of subjects from 20 to 250. The financial update revealed a $7.3 million net raise from a public offering, with operating expenses reduced by 26% on an annual basis. ENDRA's goal is to complete clinical work and submit a de novo application to the FDA by mid-2025, with the current cash runway projected to fund the company into the first half of 2025. The management reiterated their confidence in ENDRA's technology and market potential, highlighting ongoing efforts to formalize a long-term business strategy and improve financial execution.ENDRA Life Sciences Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
46
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -39.72K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.43M | -6.87M | -11.30M | -9.78M | -12.92M | -11.01M |
| Net Income | -5.92M | -7.03M | -11.51M | -10.06M | -13.18M | -11.23M |
Balance Sheet | ||||||
| Total Assets | 7.94M | 3.85M | 4.45M | 6.75M | 9.27M | 12.87M |
| Cash, Cash Equivalents and Short-Term Investments | 1.74M | 762.37K | 3.23M | 2.83M | 4.89M | 9.46M |
| Total Debt | 429.27K | 492.35K | 754.14K | 394.40K | 546.63K | 796.09K |
| Total Liabilities | 1.63M | 1.59M | 1.89M | 1.10M | 2.07M | 2.09M |
| Stockholders Equity | 6.31M | 2.26M | 2.56M | 5.66M | 7.20M | 10.78M |
Cash Flow | ||||||
| Free Cash Flow | -7.84M | -5.20M | -7.42M | -9.58M | -12.97M | -11.17M |
| Operating Cash Flow | -4.82M | -5.18M | -7.40M | -9.55M | -12.77M | -11.12M |
| Investing Cash Flow | -332.89K | -3.02M | -12.80K | -24.72K | -202.58K | -45.00K |
| Financing Cash Flow | 8.89M | 5.73M | 7.81M | 7.52M | 8.40M | 13.40M |
ENDRA Life Sciences Technical Analysis
Neutral
4.86
Price Trends
4.86
Negative
4.98
Negative
4.78
Negative
Market Momentum
-0.10
Negative
47.80
Neutral
52.29
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NDRA, the sentiment is Neutral. The current price of 4.86 is above the 20-day moving average (MA) of 4.47, above the 50-day MA of 4.86, and above the 200-day MA of 4.78, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 47.80 is Neutral, neither overbought nor oversold. The STOCH value of 52.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NDRA.
ENDRA Life Sciences Risk Analysis
ENDRA Life Sciences disclosed 46 risk factors in its most recent earnings report. ENDRA Life Sciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ENDRA Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $7.60M | -0.26 | -174.16% | ― | 38.09% | 54.22% | |
44 Neutral | $6.73M | -0.72 | -513.22% | ― | ― | 98.17% | |
42 Neutral | $4.26M | >-0.01 | -584.67% | ― | -92.11% | 86.78% | |
41 Neutral | $886.20K | >-0.01 | -337.10% | ― | -27.39% | 99.29% |
* Healthcare Sector Average
NDRA
ENDRA Life Sciences
4.56
0.47
11.49%
BNBX
BNB Plus
0.14
-3.21
-95.94%
INBS
Intelligent Bio Solutions
2.50
-12.13
-82.91%
ISPC
iSpecimen
1.57
-30.43
-95.09%
BGLC
BioNexus Gene Lab Corp
1.55
-4.04
-72.27%
ENDRA Life Sciences Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
ENDRA Regains Nasdaq Compliance, Enters One-Year Monitoring
Negative
Jul 9, 2026
ENDRA Life Sciences said that on April 20, 2026, Nasdaq notified the company that its stockholders’ equity, as reported in its 2025 annual report, fell below the $2.5 million minimum required for continued listing. After ENDRA requested a he...
Business Operations and StrategyM&A TransactionsPrivate Placements and FinancingRegulatory Filings and ComplianceStock Split
ENDRA Life Sciences to Merge, Rebrand as Noble Africa
Positive
Jun 26, 2026
On June 25, 2026, ENDRA Life Sciences Inc. signed a merger agreement under which its subsidiary Merger Sub will combine with Noble Africa LLC, leaving Noble as a wholly owned unit and transforming ENDRA into Noble Africa Inc. The deal is paired wi...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
ENDRA Life Sciences Plans Merger Creating Noble Africa Helium Platform
Positive
Jun 25, 2026
On June 25, 2026, ASP Isotopes and ENDRA Life Sciences announced a proposed merger in which ASP’s wholly owned subsidiary Noble Africa LLC will combine with a subsidiary of ENDRA, leaving Noble Africa as the surviving entity and creating a N...
Business Operations and StrategyDelistings and Listing ChangesPrivate Placements and FinancingRegulatory Filings and Compliance
ENDRA Life Sciences Announces Strategic Private Placement Financing
Positive
May 28, 2026
On May 27, 2026, ENDRA Life Sciences entered into a private placement securities purchase agreement with an accredited investor to sell 578,387 shares of common stock and/or prefunded warrants, plus common warrants for up to 1,156,774 additional s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.